Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

BMS's $75mm ion channel collaboration with ICAgen

Executive Summary

Bristol-Myers Squibb and ICAgen (ion channel drugs) will jointly discover and develop small molecule cardiovascular drugs through ion channel modulation, in a two-year agreement, with an option for a third year, worth a potential $75mm to ICAgen.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register